Skip to main content

Table 3 Risk factors for AIDS incidence during the follow-up among patients newly diagnosed with HIV infection

From: AIDS incidence trends at presentation and during follow-up among HIV-at-risk populations: a 15-year nationwide cohort study in Taiwan

 

Number of patients, n

Number of AIDS, n

%

Univariable analysis, crude HR (95% CI)

Multivariable analysis, adjusted HR (95% CI)

Age group

  ≤ 30

9826

843

8.6

1.0 (Reference)

1.0 (Reference)

 31–40

5312

442

8.3

0.97 (0.87–1.09)

1.17 (1.04–1.32)**

 41–50

2028

227

11.2

1.35 (1.16–1.56)***

1.68 (1.44–1.96)***

  ≥ 51

737

127

17.2

2.19 (1.82–2.64)***

2.36 (1.90–2.92)***

Sex

 Female

1302

96

7.4

1.0 (Reference)

1.0 (Reference)

 Male

16,601

1543

9.3

1.26 (1.03–1.55)*

1.16 (0.93–1.44)

HIV-transmission route

 PWID

6435

361

5.6

1.0 (Reference)

1.0 (Reference)

 Bisexual contact

1322

148

11.2

2.05 (1.69–2.48)***

2.62 (2.11–3.24)***

 Heterosexual contact

2496

312

12.5

2.33 (2.00–2.71)***

2.79 (2.35–3.31)***

 Homosexual contact

7602

808

10.6

1.94 (1.71–2.19)***

2.58 (2.19–3.03)***

 Othera

48

10

20.8

4.92 (2.62–9.22)***

4.90 (2.58–9.31)***

Urbanization

 Rural

6038

557

9.2

1.0 (Reference)

1.0 (Reference)

 Urban

11,865

1082

9.1

0.99 (0.89–1.09)

0.93 (0.83–1.04)

Income level, n (%)

 Low

11,323

950

8.4

1.0 (Reference)

1.0 (Reference)

 Intermediate

4833

508

10.5

1.26 (1.13–1.41)***

0.97 (0.86–1.08)

 High

1747

181

10.4

1.24 (1.06–1.46)**

0.84 (0.71–0.99)*

Cohort period

 Period 1

957

43

4.5

1.0 (Reference)

1.0 (Reference)

 Period 2

1777

68

3.8

0.85 (0.58–1.24)

0.82 (0.56–1.21)

 Period 3

6890

559

8.1

1.84 (1.35–2.51)***

3.32 (2.42–4.56)***

 Period 4

3976

458

11.5

2.67 (1.95–3.65)***

3.53 (2.57–4.84)***

 Period 5

4303

511

11.9

2.76 (2.02–3.76)***

3.04 (2.22–4.17)***

Region

 Taipei area

6166

526

8.5

1.0 (Reference)

1.0 (Reference)

 Northern Taiwan

2581

279

10.8

1.28 (1.11–1.48)***

1.41 (1.22–1.64)***

 Central Taiwan

3209

275

8.6

1.00 (0.87–1.16)

1.06 (0.91–1.23)

 Southern Taiwan

2137

197

9.2

1.09 (0.92–1.28)

1.17 (0.98–1.38)

 Kaoping area

3466

324

9.4

1.10 (0.96–1.27)

1.14 (0.98–1.32)

 Eastern Taiwan

344

38

11.1

1.30 (0.94–1.81)

1.16 (0.82–1.64)

DM

 No

17,556

1590

9.1

1.0 (Reference)

1.0 (Reference)

 Yes

347

49

14.1

1.69 (1.27–2.25)***

1.08 (0.79–1.46)

CKD

 No

17,717

1610

9.1

1.0 (Reference)

1.0 (Reference)

 Yes

186

29

15.6

1.89 (1.31–2.73)***

1.49 (1.02–2.17)*

CHF

 No

17,861

1630

9.1

1.0 (Reference)

1.0 (Reference)

 Yes

42

9

21.4

2.82 (1.46–5.43)**

1.81 (0.92–3.58)

COPD

 No

17,626

1604

9.1

1.0 (Reference)

1.0 (Reference)

 Yes

277

35

12.6

1.47 (1.05–2.05)*

1.00 (0.71–1.41)

Cancer

 No

16,788

1506

9.0

1.0 (Reference)

1.0 (Reference)

 Yes

1115

133

11.9

1.38 (1.15–1.64)***

1.09 (0.91–1.31)

CVD

 No

17,765

1622

9.1

1.0 (Reference)

1.0 (Reference)

 Yes

138

17

12.3

1.47 (0.91–2.36)

1.01 (0.62–1.65)

HAART during follow-up period

 No

5173

120

2.3

1.0 (Reference)

1.0 (Reference)

 Yes

12,730

1519

11.9

1.43 (1.29–1.59)***

1.29 (1.15–1.44)***

  1. Note. * P < 0.05; ** P < 0.001; *** P < 0.001
  2. Abbreviation: AIDS acquired immunodeficiency syndrome, CHF chronic heart failure, CI confidence intervals, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, DM diabetes mellitus, HAART highly active antiretroviral therapy, HR hazard ratios, PWID people who injected drugs
  3. aIncludes those exposed to blood products, mother-to-child transmission, and unknown exposures
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us